Neptune Technologies preclinical data

In a rat model of severe dyslipidemia and Type II diabetes, human equivalent dosing with 0.5 g/day of Acasti Pharma Inc.'s CaPre long-chain omega-3 phospholipids for 12 weeks significantly reduced imp...